1. Home
  2. GNLX vs ORGO Comparison

GNLX vs ORGO Comparison

Compare GNLX & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genelux Corporation

GNLX

Genelux Corporation

N/A

Current Price

$1.99

Market Cap

110.4M

Sector

Health Care

ML Signal

N/A

Logo Organogenesis Holdings Inc.

ORGO

Organogenesis Holdings Inc.

N/A

Current Price

$0.84

Market Cap

127.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GNLX
ORGO
Founded
2001
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.4M
127.6M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
GNLX
ORGO
Price
$1.99
$0.84
Analyst Decision
Strong Buy
Hold
Analyst Count
6
2
Target Price
★ $18.83
$2.00
AVG Volume (30 Days)
439.5K
★ 1.1M
Earning Date
11-17-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
9.47
★ 1600.00
EPS
★ N/A
N/A
Revenue
$8,000.00
★ $564,169,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$37.55
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 17.04
52 Week Low
$1.86
$0.73
52 Week High
$6.26
$7.08

Technical Indicators

Market Signals
Indicator
GNLX
ORGO
Relative Strength Index (RSI) 40.08 39.51
Support Level $1.86 N/A
Resistance Level $2.82 $2.58
Average True Range (ATR) 0.23 0.09
MACD -0.02 0.01
Stochastic Oscillator 21.97 43.09

Price Performance

Historical Comparison
GNLX
ORGO

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

About ORGO Organogenesis Holdings Inc.

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Share on Social Networks: